



**THE AURUM
INSTITUTE**



CLINICAL RESEARCH

Klerksdorp CRS

Rustenburg CRS

Tembisa CRS

Fundação Aurum

Pretoria CRS



2005



2008



2008



2019



2020

**Established to
conduct HIV Vaccine
Trials**

46 trials
>17 800 enrolled

**Established to
conduct HIV
Epidemiology Studies
to prepare for HIV
Vaccine Trials**

47 trials
>17 000 enrolled

Established to conduct
TB Treatment Trials
Consists of 2 CRS's
(C1&2, C3&4)
C1&2
42 Studies/Trials
> 3 600 enrolled
C3&4
12 Studies/Trials
> 2 400 enrolled

Established in
Mozambique to aid roll
out of 3HP & Covid-19
self-testing and prepare
for TPT Phase 3
and 4 trials.

1 Trial
> 22 enrolled

**Acquired to conduct
Pharma & PK Trials**

78 trials
> 3 400 enrolled



Conducted **>224 trials** and research studies in the past 18 years focusing on:

- HIV vaccines & prevention (oral, topical, and long-acting injectable PrEP)
- TB treatment, Host-directed therapy, TB vaccines & TB preventative therapy
- COVID-19 vaccines, -COVID-19 mAb & COVID-19 treatment
- Diagnostics and socio-behavioral studies.

Enrolled **>67 565** participants in trials and research studies (Clinical Research Division)

- **>23 500** Thibela TB (enrollment at mine shafts)
- **>25 500** Sisonke vaccine roll-out to Healthcare Workers (enrollment at Department of Health Vaccination Sites)
- **>18 513** enrolled in remaining trials and research studies (enrollment at 6 Clinical Research Sites)

Aurum's distinct strengths:

- CRS pluripotency
- Collective scientific, operational & management experience of its research leadership
- High-functioning resources & systems to effectively implement large-scale complex clinical trials (both network & Investigator-lead)

Each CRS brings a unique complement of skills, populations, facilities, and experience

PROGRAMMATIC AREAS




COVID-19



TB Treatment



TB Vaccines



HIV Treatment and PrEP



HIV Vaccines



Special Projects



HIV PREVENTION VACCINES

	2006	2007	2011	2012	2013	2015	2016	2017	2018	2021	2022	TOTAL	
PHASE I			IAVI B003 27 Ppts	HVTN 086 62 Ppts	HVTN 097 33 Ppts	HVTN 100 36 Ppts	HVTN 108 16 Ppts HVTN 111 28 Ppts				HVTN 139 6 Ppts		Klerksdorp Total 208 Participants
							HVTN 108 16 Ppts HVTN 111 20 Ppts	HVTN 107 36 Ppts			IAVI G003 9 Ppts		Tembisa Total 81 Participants
PHASE II/III		HVTN 204 80 Ppts	HVTN 503 221 Ppts				HVTN 702 353 Ppts	HVTN 703 15 Ppts	HVTN 705 55 Ppts				Klerksdorp Total 724 Participants
							HVTN702 290 Ppts	HVTN703 18 Ppts	HVTN705 66 Ppts				Tembisa Total 374 Participants
							HVTN702 358 Ppts	HVTN703 37 Ppts	HVTN705 52 Ppts				Rustenburg Total 447 Participants

TB VACCINES

	2009	2011	2014	2012	2015	2020	2021	2023	2024	TOTAL	
PHASE I					AERAS C037-456 6 Ppts			BNT 164-02 53 Ppts			Tembisa Total 59 Participants
									H107/nTB01 23 Ppts		Pretoria Total 23 Ppts
PHASE II/III		AERAS 402 26 Ppts	GSK TB-018 325 Ppts				AERAS-A055 91 Ppts	MESA TB 85 Ppts	HVTN 605 17 Ppts CommuniTB 45 Ppts HVTN 603 & 604 Pending		Klerksdorp Total 589 Participants
			Aurum 102 24 Ppts	GSK TB-018 52 Ppts			AERAS-A055 66 Ppts		CommuniTB 204 +47 Ppts		Tembisa Total 393 Participants
									HVTN 603 & 604 Pending CommuniTB 88 Ppts HVTN 605 7 Ppts IAVI C113 Pending		Rustenburg Total 95 Participants

TB PREVENTION & TREATMENT

	2008	2011	2012	2013	2014	2015	2016	2017	2018	2019	2021	2022	2023	2024	TOTAL	
						NC006 2 Ppts	CORTIS-01 392 Ppts	CORTIS HR 160 Pts					One to Three 250 Ppts			Klerksdorp Total 804 Participants
	Rifaquin 255 Ppts	Remox 4 Ppts	NC002 7 Ppts	MAMS-TB01 15 Ppts	NC005 14 Ppts	NC006 22 Ppts	TB-HDT 105 Ppts	WHIP3TB 660 Ppts	DOLPHIN 61 Ppts		Sudocu 4 Ppts Method 73 Ppts	DOLPHIN Too 75 Ppts DBO 17 Ppts Decode 11 Ppts	DR7B-HDT 33 Ppts Infin TB 162 Ppts DOLPHIN Moms 22 Ppts	Pan TB 40 Ppts		Tembisa Total 1580 Participants
						NC006 18 Ppts	CORTIS-01 411 Ppts	CORTIS HR 161 Pts WHIP3TB 233 Ppts		PHOENix 162 Ppts	BPamZ/SEM 7 Ppts		A5356 5 Ppts	NC009 15 Ppts		Rustenburg Total 1012 Participants
												BDO3-201 1 Ppts	DOLPHIN Kids 5 Ppts			Pretoria Total 6 Participants

HIV PREVENTION, STIs & CONTRACEPTION

2010	2011	2012	2015	2016	2017	2021	2022	2023	2024	TOTAL
VOICE 263 Pts				ECHO 555 Pts		Impower 18 Ppts	Purpose 171 Ppts INSIGHT 165 Ppts		MATRIX 002 13 Ppts	Klerksdorp Total 1 185 Participants
	Facts 01 191 Ppts						Purpose 140 Ppts	Purpose 2 32 Ppts	Matrix 003 Pending Activation	Tembisa Total 363 Participants
	Facts 01 181 Ppts				Youth Friendly Services 195 Ppts	Impower 29 Ppts	Purpose 129 Ppts INSIGHT 175 Ppts		MAGY 405 Ppts	Rustenburg Total 1114 Participants
							Purpose 142 Ppts	Purpose 2 52 Ppts		Pretoria Total 194 Participants

18 Trials

COVID-19 VACCINES

	2020	2021	2022	TOTAL
PHASE II/III	Ensemble 183 Ppts	Sisonke 13 311 Ppts, CoVPN 3008 301 Ppts	CEPI 155 Ppts Sherpa 162 Ppts	Klerksdorp Total 14 112 Participants
	Ensemble 302 Ppts	Sisonke CoVPN 3008 333 Ppts	WANTAI 50 Ppts CEPI 150+140 Ppts Sherpa 527 Ppts	Tembisa Total 1 502 Participants
	Ensemble 191 Ppts	Sisonke 9 880 Ppts CoVPN 3008 309 Ppts	CEPI 169 Ppts Sherpa 240 Ppts	Rustenburg Total 10 789 Participants
	Ensemble 2 256 Ppts, Novavax 501 152 Ppts	Sisonke 2 360 Ppts	Novavax 505 17 Ppts CEPI 80 Ppts Sherpa 175 Ppts	Pretoria Total 3 040 Participants

22 Trials

We have seen the impact of clinical trials saving millions of lives in the COVID-19 pandemic and we are now even more committed to continue our search for safer, more effective tools to address the continuing TB and HIV pandemics!

FIND US ONLINE



The Aurum Institute

www.auruminstitute.org

2023 AT A GLANCE

320 Employees

Staff Diversity
81% Black, 4% Coloured,
4% Indian & 12% White
(69% Female)

6 Clinical Research Sites

1 Overnight/PK facility

4 Routine Laboratories

1 Basic Research Lab
which includes a BSL-3
mycobacteriology lab

1 Biorepository

4 Registered
Pharmacies

33 Funders

62 Clinical Trials
12 Closeout activities
40 Active at end of 2023

5673 Participants
(Enrolled and followed up in 2023)

30 Vaccine
& bNAb Trials

31 Treatment &
Prevention Trials

11 Aurum Led Trials

22 CRD Publications:
5 first or senior author
9 high impact publications
[IF > 6]